India drafted tougher drug patent rules to block evergreening

What's going on here?

On 16 October 2026, the Office of the Controller General of Patents, Designs and Trade Marks issued draft guidelines to overhaul how pharmaceutical patent applications are examined in India. The document targets evergreening, where companies file follow-on patents on small changes to known molecules to delay generic competition. The draft requires practical scientific proof that a claimed invention improves treatment, not abstract wording. Variations such as new salts, crystal forms, or derivatives need comparative research showing a meaningful jump in efficacy. Commercial perks like easier manufacturing or faster absorption will not qualify unless backed by tests in living models. The framework also limits sprawling Markush claims that cover huge chemical families without synthesis detail, and it folds in court tests used since 2013 to judge novelty and obviousness.

What does this mean?

India’s drug industry runs about $60 billion in sales and ranks among the largest generic exporters by volume. When primary patents expire, local manufacturers such as Cipla, Sun Pharma, and Dr. Reddy’s can launch low-cost copies, which matters for both domestic patients and emerging-market buyers. Stricter examination makes it harder to win secondary patents that stretch exclusivity after the main compound patent ends. Innovators argue they need protection for genuine improvements; domestic associations such as the Indian Drug Manufacturers’ Association welcomed the balance toward affordability. Recent disputes over semaglutide and spinal muscular atrophy drug Risdiplam show how much revenue rides on whether a follow-on patent is treated as a real invention or a monopoly extension.

Why should I care?

If you pay out of pocket for chronic medicines, faster generic entry can eventually widen choices and pressure prices, though court battles may still delay specific launches. Investors in Indian pharma should separate pipeline bets on complex biologics from routine generic launches that benefit when examiners reject weak patents. Multinational patent holders must budget for harder evidence standards in India. Watch the comment period on the draft guidelines, Delhi High Court rulings cited in the text, and whether Parliament pairs patent tightening with separate data-protection rules some innovators are requesting.